about us

Tissue & Cell Technologies was conceived to develop advanced, effective and safe products and services for use in the clinical management of human tissue and cells.

about us

Tissue & Cell Technologies was conceived to develop advanced, effective and safe products and services for use in the clinical management of human tissue and cells.

These products and services include our adipose tissue harvest and storage service – Adiposet™ , and Regenerys™ – products for skin regeneration in cosmetic/aesthetic medicine. Adipose derived approaches show potential in the treatment of burns and chronic wounds.

The services and products we provide are built on solid pillars of quality and regulatory compliance.

These products and services are provided to the NHS and to qualified private healthcare providers.

These products and services include our adipose tissue harvest and storage service – Adiposet™ , and Regenerys™ – products for skin regeneration in cosmetic/aesthetic medicine. Adipose derived approaches show potential in the treatment of burns and chronic wounds.

The services and products we provide are built on solid pillars of quality and regulatory compliance.

These products and services are provided to the NHS and to qualified private healthcare providers.

T&CT’s business and core development team trace their beginnings back to 2000 and research work conducted in Sheffield into bio-materials and the uses of human tissue, particularly adipose, fat and keratinocytes (skin cells).

This research matured and the first product, a suspension of cultured skin cells for the treatment of extreme burns as an alternative to physical skin grafts, was introduced into the U.K. market. The two variants, MySkin™ and CryoSkin™, have been used as treatment of last resort for extreme burns victims since 2008 at all 5 of the U.K.’s major burns centres.

T&CT’s business and core development team trace their beginnings back to 2000 and research work conducted in Sheffield into bio-materials and the uses of human tissue, particularly adipose, fat and keratinocytes (skin cells).

This research matured and the first product, a suspension of cultured skin cells for the treatment of extreme burns, as an alternative to physical skin grafts, was introduced into the U.K. market. The two variants, MySkin™ and CryoSkin™, have been used as treatment of last resort for extreme burns victims since 2008 at all 5 of the U.K.’s major burns centres.

Out of this work, the team adapted its technology to the processing & storage of adipose tissue, with the initial objective of producing a product & service for breast reconstruction for women who have had mastectomies following breast cancer. These products, all under the Adiposet™ banner, received excellent results in the multi-centre clinical trials for Safety & Efficacy, and were launched commercially into the NHS in 2014 Since launching, Adiposet™ has been used in over 25 NHS hospital trusts and is widely available for use under existing NICE guidelines. Patients are particularly pleased with the treatment and many doctors are now saying that with fat grafting technology maturing as a partial or complete alternative to implants or flap surgery, it is destined to be the new Gold Standard for breast reconstruction.

Since 2018 T&CT has entered 3 further detailed clinical studies at Nottingham University Hospital, London’s Guys & St Thomas’s and at Oxford University’s John Radcliffe Hospital exploring various aspects of Adiposet™’s performance, including its comparative cost advantages versus current procedures.

Out of this work, the team adapted its technology to the processing & storage of adipose tissue, with the initial objective of producing a product & service for breast reconstruction for women who have had mastectomies following breast cancer. These products, all under the Adiposet™ banner, received excellent results in the multi-centre clinical trials for Safety & Efficacy, and were launched commercially into the NHS in 2014 Since launching, Adiposet™ has been used in over 25 NHS hospital trusts and is available for use under existing NICE guidelines. Patients are particularly pleased with the treatment and many doctors are now saying that with fat grafting technology maturing as a partial or complete alternative to implants or flap surgery, it is destined to be the new Gold Standard for breast reconstruction.

Since 2018 T&CT has entered 3 further detailed clinical studies at Nottingham University Hospital, London’s Guys & St Thomas’s and at Oxford University’s John Radcliffe Hospital exploring various aspects of Adiposet’s performance, including its comparative cost advantages versus current procedures.

T&CT continued its R&D with the development of Regenerys™, a small volume fat grafting/injection product as an ‘all-natural’ alternative to cosmetic facial fillers. Partnering with a team of gifted specialists in the field of Plastic Surgery, T&CT’s Regenerys™ product is now exclusively available in the U.K. in London’s top plastic surgery clinics, and is planned for broader roll-out in 2021.

T&CT has also responded to calls by a number of reconstructive surgeons and plastic surgeons to make the service available in overseas markets with the planned launch of fully staffed local operations in Dubai and Europe. Both Adiposet™ and Regenerys™ will then be available across all 3 regions, backed by leading clinics and surgeons. Our advanced proprietary skin grafting products, MySkin™ and CryoSkin™ will also be launched into the Middle East.

T&CT continued its R&D with the development of Regenerys™, a small volume fat grafting/injection product as an ‘all-natural’ alternative to cosmetic facial fillers. Partnering with a team of gifted specialists in the field of Plastic Surgery, T&CT’s Regenerys™ product is now exclusively available in the U.K. in London’s top plastic surgery clinics, and is planned for broader roll-out.

T&CT has also responded to calls by a number of reconstructive surgeons and plastic surgeons to make the service available in overseas markets with the planned launch of fully staffed local operations in Dubai and Europe starting in early 2021. Both Adiposet™ and Regenerys™ will then be available across all 3 regions, backed by leading clinics and surgeons. Our advanced proprietary skin grafting products, MySkin™ and CryoSkin™ will also be launched into the Middle East.

T&CT is also building on its tissue handling skillset by partnering with selected businesses in developing new products using autologous stem-cells and other tissue. Early results from its collaboration in hair growth & follicle stimulation are extremely promising and is now accelerating into early commercialisation and clinical development.

The emergence, more broadly, of highly anticipated therapies and products based on autologous tissue engineering and manipulation now means that T&CT is well positioned for rapid growth as one of the few commercial operations worldwide with the skills, regulatory framework, and track record of clinical delivery to deliver end-to-end tissue handling & storage services to larger partners.

T&CT is also building on its tissue handling skillset by partnering with selected businesses in developing new products using autologous stem-cells and other tissue. Early results from its collaboration in hair growth & follicle stimulation are extremely promising and is now accelerating in early commercialisation and clinical development.

The emergence, more broadly, of highly anticipated therapies and products based on autologous tissue engineering and manipulation now means that T&CT is well positioned for rapid growth as one of the few commercial operations worldwide with the skills, regulatory framework, and track record of clinical delivery to deliver end-to-end tissue handling & storage services to larger partners.

T&CT expects to find valuable research avenues and commercial collaborations in the following avenues over the next few years:
• hair regrowth & follicle stimulation
• wound healing & skin grafts for diabetes related conditions
• ‘complete’ autologous breast reconstruction, not as an augmentation service to implants or flap surgery
• ‘custom-tuned’ autologous Stem Cell based regenerative & rejuvenative fillers for aesthetic and reconstructive applications
• Stem Cell based autologous tissue products to address long term problems requiring serious revision & correction surgery & procedures
• heart muscle & cell regeneration and patches

T&CT expects to find interesting research avenues and commercial collaborations in the following avenues over the next few years:
• hair regrowth & follicle stimulation
• wound healing & skin grafts for diabetes related conditions
• ‘complete’ autologous breast reconstruction, not as an augmentation service to implants or flap surgery
• ‘custom-tuned’ autologous Stem Cell based regenerative & rejuvenative fillers for aesthetic and reconstructive applications
• Stem Cell based autologous tissue products to address long term problems requiring serious revision & correction surgery & procedures
• heart muscle & cell regeneration and patches

T&CT is the U.K. leader in human adipose tissue management and has expanded its scope to work closely with some of the U.K.’s pre-eminent clinics and research groups and under the guidance of some of the U.K.’s leading plastic and reconstructive surgeons in the ongoing development of our technology and management processes.

Company Timeline

2000

Core research team starts work on autologous skin cell products.

2005

Successful MHRA accreditation under the Code of Practice for Tissue Banks and the Code of Practice for the Production of Human-derived therapeutic Products.

2010

Joint HTA/MHRA inspection for Altrika for GMP Manufacturer’s Specials Licence and tissues and cells for human application.

2014

Multi-center clinical study info safety & efficacy of Adiposet product and system.

2017

Launched Adiposet product for breast reconstruction into U.K.’s NHS

2019

Restructured operations to focus efforts on establishing strong business line in breast reconstruction and to facilitate development and launch of Regenerys cosmetic filler products.

2020

Milestone: 200 women successfully treated with Adiposet breast reconstruction
Regenerys cosmetic filler product launched into U.K. market

2021

Pilot launch for Adiposet planned for Sydney, Australia & UAE.

2004

CellTran Limited formed

First round venture fund raising >£1 million

2005

Successful MHRA accreditation under the Code of Practice for Tissue Banks and the Code of Practice for the Production of Human-derived therapeutic Products.

2006

Human Tissue Authority Licence granted for the procurement, testing, processing, storage, distribution and import/export of human tissue for human application
Funding for development of technology and intellectual property to a new therapeutic/elective indication
Acquisition of assets including a medicinal product, medical device and GMP banked cell line

2007

Contract manufacturing and collaboration agreements and associated technical and quality agreements for the GMP processing of mesenchymal stem-cells for future therapeutic applications

2008

Key contributing member of U.K. and European consortia successfully accessing multi-million pound grant funding (>£2.75 million grant funding for projects totalling >£4.5 million)
Granted a Manufacturer’s Specials Licence for an allogeneic skin cell product following a GMP inspection by MHRA

2009

Altrika Limited formed to develop and commence production and delivery of critical burns products – MySkin™ and CryoSkin™ to NHS burns centres

2010

Joint HTA/MHRA inspection for Altrika for GMP Manufacturer’s Specials Licence and tissues and cells for human application

2011

Regenerys Ltd formed to commercialise breast reconstruction service into NHS and EU

2012

Novel adipose tissue storage process, including GMP manufacture, regulatory approvals as well as ethical approval for a multi-centre NHS clinical study

2014

Training and clinical liaison with multiple NHS sites for trial and adoption of adipose tissue banking service
NICE approval for Adiposet™ product to NHS

2016

Completed multi-centre clinical trial
Launched commercial Adiposet™ clinical product in UK

2016

Tissue and Cell Technologies formed to roll out Adiposet™ and Regenerys™ products worldwide
Research agreement signed with Guys & St Thomas’s NHS Trust for clinical study into breast reconstruction

2020

Launched our proprietary Regenerys™ cosmetic product in UK
Research agreement signed with John Radcliffe Oxford University Hospital NHS Trust for clinical study into reconstructive plastic surgery

2020

Pilot launch for Adiposet™ and Regenerys™ planned for Europe. Local KOL’s and partners identified.
Pilot launch for Adiposet™ and Regenerys™ planned for UAE. Local KOL’s and partners identified.